Identifying reliable biomarkers of disease activity in granulomatosis with polyangiitis is the goal of a collaboration between Cleveland Clinic and Case Western Reserve University
Study findings support the addition of a conventional maintenance agent, in the absence of contraindications, with rituximab to reduce the risk of relapse in granulomatosis with polyangiitis patients.
GPA (Wegener’s) characteristically has a relapsing course, and studies support continuing maintenance medications for at least 36 months.
Giant cell arteritis and Takayasu’s arteritis may not be separate diseases but rather skewed phenotypes of a single disease, influenced by genetics, age-related structural changes, immunologic senescence and environment.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Addition of a conventional maintenance agent to rituximab and glucocorticoids reduced the incidence of GPA relapse without resulting in a higher incidence of adverse events in study.